10-K: ZyVersa Therapeutics Faces Delisting, Impairment Amidst Losses

ZyVersa Therapeutics, a clinical-stage biopharmaceutical company, reported a significant net loss of $25.0 million in 2025, including an $18.6 million impairment charge, and was delisted from Nasdaq, raising substantial doubt about its going concern ability.

Summary

• ZyVersa Therapeutics is a clinical-stage biopharmaceutical company developing drugs for chronic renal or inflammatory diseases using two proprietary platforms: Cholesterol Efflux Mediator™ VAR 200 and Inflammasome ASC Inhibitor IC 100.
• VAR 200, an injectable drug for renal diseases, is in clinical development with a Phase 2a basket trial planned for FSGS and Alport syndrome patients in Q2-2026.
• IC 100, a humanized monoclonal antibody for inflammatory conditions, is in preclinical development with an IND submission planned for Q4-2026, followed by a Phase 1 trial.
• The company reported a net loss of $25.0 million for the year ended December 31, 2025, a significant increase from $9.4 million in 2024.
• An $18.6 million impairment charge related to in-process research and development (IPR&D) was recorded in 2025 due to a sustained decline in market capitalization and difficulties accessing capital.
• ZyVersa's common stock was delisted from The Nasdaq Capital Market on October 6, 2025, and now trades on the OTCQB Venture Market under the symbol ZVSA.
• As of December 31, 2025, the company had an accumulated deficit of approximately $137.6 million and a cash balance of $0.1 million.
• Management believes current cash is only sufficient to fund operating expenses and capital expenditure requirements on a month-to-month basis, necessitating additional financing.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing with a highly negative sentiment due to significant financial losses, a substantial impairment charge, delisting from Nasdaq, and explicit 'going concern' doubt, indicating severe operational and financial distress despite ongoing development efforts.

Positives

• VAR 200 has pharmacologic proof-of-concept data in animal models representative of FSGS, Alport Syndrome, and diabetic kidney disease.
• IC 100 non-GLP toxicology data in mice and non-human primates demonstrate no adverse effects nor anti-drug antibodies at doses up to 300 mg/kg, indicating a good safety profile.
• IC 100 has preclinical data substantiating its mechanism of action in both CNS and Non-CNS diseases.
• The PARASOL project supports the use of 2-year changes in proteinuria as an endpoint for FSGS drug approval, potentially shortening the regulatory path for VAR 200.
• The global renal drug market was $20 billion in 2024 and is projected to reach $30 billion by 2034, indicating a growing market for VAR 200.
• The global anti-inflammatory biologics market was valued at $104.81 billion in 2024 and is projected to reach $185.51 billion by 2034, suggesting a large potential market for IC 100.
• Successfully raised approximately $1.0 million through a Securities Purchase Agreement on February 27, 2026, after the fiscal year end.

Negatives

• Reported a significant net loss of $25.0 million in 2025, a substantial increase from $9.4 million in 2024.
• Incurred an $18.6 million impairment charge on in-process research and development (IPR&D) due to a sustained decline in market capitalization and limitations on accessing capital.
• Delisted from The Nasdaq Capital Market on October 6, 2025, and now trades on the OTCQB Venture Market, which generally has substantially less liquidity.
• Accumulated deficit of approximately $137.6 million as of December 31, 2025.
• Cash balance of $0.1 million as of December 31, 2025, is only sufficient to fund operations on a month-to-month basis.
• Working capital deficiency of approximately $12.4 million as of December 31, 2025.
• Has never been profitable and does not expect to be profitable for the foreseeable future.
• Relies heavily on third parties for manufacturing, storage, and testing of product candidates.
• Faces intense competition from companies with substantially greater financial, technical, and human resources.
• One vendor accounted for 56% of accounts payable related to research and development as of December 31, 2025 and 2024, indicating high vendor concentration risk.
• Disputed vendor invoices totaling $1,066,978 for unaccrued interest and unsupported charges, which are not recorded as a liability as of December 31, 2025, but represent a potential future liability.

Risks

• Ability to continue as a going concern due to significant losses and the need for additional capital.
• Costs associated with the business and the ability to achieve and maintain profitability in the future.
• Ability to effectively grow and expand operations.
• Risk of disruption to current plans and operations, including those caused by catastrophic events.
• Ability to maintain the quotation of securities on the OTCQB Venture Market, and the potential for reduced liquidity and trading of securities.
• Ability to recognize the anticipated benefits of the business, which may be affected by the ability to grow and manage research and development and clinical activity, and retain key employees.
• Impact of changes to applicable laws or regulations.
• Future capital requirements and sources and uses of cash, including the ability to access sources of capital or raise financing in the future.
• Ability to maintain existing license agreements and other collaborative arrangements.
• Ability to obtain and maintain regulatory approval for product candidates, and any related restrictions and limitations of any approved products.
• Success, cost, and timing of research and development strategies and activities.
• Ability to successfully launch product candidates and achieve market acceptance.
• Ability to compete with competitors, many of whom have substantially greater financial, technical, and human resources.
• Ability to attract and retain talent and the effectiveness of compensation strategies and leadership.
• Ability to maintain licenses and operate in the heavily regulated pharmaceutical industries.
• Ability to prevent and guard against cybersecurity attacks.
• Reliance on third-party service providers for processing payments, web and mobile operating systems, software, background checks, and insurance policies.
• Ability to establish and maintain an effective system of internal controls over financial reporting.
• Outcome of any known and unknown litigation and regulatory proceedings.
• Ability to maintain and protect intellectual property.
• The common stock is likely to be subject to 'penny stock' rules for the foreseeable future, which could impede sales and decrease liquidity.
• Uncertainty regarding the timing and costs of completing product development and achieving regulatory approval.
• Dependence on third-party suppliers and manufacturing organizations for all raw materials and drug substance.
• Significant financial and management resources required to establish commercial infrastructure prior to any product approval.
• No guarantee that licensed patents will be upheld if challenged by a third party.
• Regulatory approval, if obtained, may be limited to specific disease states, patient populations, and dosages, or contain significant limitations.
• New government requirements or changes in FDA policies could delay or prevent regulatory approval.
• Failure to comply with post-marketing FDA regulations could result in severe enforcement actions.
• Government coverage and reimbursement policies will directly and indirectly affect the ability to successfully commercialize products.
• Exposure to international data privacy and security laws, such as GDPR and PIPEDA, with potential for significant penalties for non-compliance.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it progresses the development of VAR 200 and IC 100, prepares regulatory submissions, and builds manufacturing and commercial infrastructure. Additional financing will be needed to fund operations and complete product development, with no assurance of availability on acceptable terms. Profitability is not expected in the near future.

Management Comments

• "We believe that each of our product candidates has the potential to treat numerous indications in their respective therapeutic areas."
• "Our strategy is to focus on indication expansion to maximize commercial potential."
• "We believe that VAR 200 has the potential to help reduce the number of patients developing renal failure by mediating removal of excess renal cholesterol and lipids."
• "By targeting ASC, we believe IC 100 has potential to effectively control inflammation in a multitude of inflammatory diseases."
• "We seek to be recognized as a leading biopharmaceutical company at the forefront of innovation for patients with high unmet medical needs."
• "We are committed to restoring health and transforming the lives of patients through development of biopharmaceutical products."
• "Management believes that the Company has access to capital resources and continues to evaluate additional financing opportunities."

Industry Context

StockSavvy.ai notes that the biopharmaceutical industry is highly competitive, with many larger companies possessing greater resources. The company's focus on rare diseases like FSGS and specific inflammatory pathways (ASC inhibition) positions it in niche but growing markets. The global renal drug market is projected to reach $30 billion by 2034, and the anti-inflammatory biologics market $185.51 billion by 2034, driven by increasing chronic disease incidence and technological advancements. The PARASOL project's recommendation for proteinuria as a surrogate endpoint for FSGS drug approval could expedite development for VAR 200, aligning with industry efforts to streamline rare disease drug pathways. However, the company's financial struggles and delisting contrast sharply with the significant capital inflows often seen in successful biotech ventures, highlighting the challenges for smaller, clinical-stage firms in a risk-averse investment climate.

Comparison to Industry Standards

• The global renal drug market was $20 billion in 2024 and is projected to reach $30 billion by 2034, indicating a growing market for VAR 200.
• The global anti-inflammatory biologics market was valued at $104.81 billion in 2024 and is projected to reach $185.51 billion by 2034, suggesting a large potential market for IC 100.
• Morgan Stanley projects global sales of GLP-1 drugs to reach $105 to $144 billion by 2030, highlighting a significant trend in obesity-related treatments that IC 100 could potentially complement as an add-on.
• Competitors in FSGS have products in Phase 2 and Phase 3 development, while VAR 200 is planning a Phase 2a trial, indicating it is behind some competitors in clinical progression.
• IC 100 is believed to be the only monoclonal antibody targeting the ASC component of the inflammasome, potentially offering a differentiated mechanism compared to competitors mainly targeting NLRP3 inflammasome pathways (e.g., those with clinical trials in obesity-related cardiometabolic comorbidities, osteoarthritis, recurrent pericarditis, and Parkinson's disease).

Management Changes

Corporate Governance

Legal Proceedings

• Not currently subject to any material legal proceedings.
• May from time to time become a party to various legal proceedings arising in the ordinary course of business.
• Litigation, regardless of outcome, can have an adverse impact due to defense and settlement costs, diversion of management resources, and other factors.

Related Party Transactions

• L&F Research LLC (founded by VAR 200 inventors/researchers at University of Miami) is a related party through the license agreement, involving milestone payments and royalty payments.
• InflamaCORE, LLC (founded by IC 100 inventors/researchers at University of Miami) is a related party through the license agreement, involving milestone payments, royalty payments, and sublicense obligations.
• University of Miami (where both drug platforms were discovered) is a related party, receiving royalty payments from InflamaCORE License Agreement and previously issued shares.
• Stephen C. Glover (CEO) is the managing director of MedicaRx Inc., the managing director of Asclepius Master Fund, LTD, and the managing member of Asclepius Life Sciences Fund, LP, which hold shares and options/warrants.
• The company has a related person transaction policy requiring audit committee review for transactions exceeding $120,000.

Stakeholder Impact

• Shareholders face significant dilution risk from future equity raises, reduced liquidity and potential price volatility due to delisting from Nasdaq to OTCQB, and substantial doubt about the company's ability to continue as a going concern.
• Employees may experience potential impact on job security and compensation due to financial distress and ongoing losses.
• Future customers could benefit from innovative drug therapies for chronic renal and inflammatory diseases, but delays in development and regulatory approval could impact product availability.
• Suppliers and vendors face a risk of delayed payments, as evidenced by the disputed vendor invoices and interest accrual.
• Creditors face increased risk due to the company's significant working capital deficiency and the auditors' 'going concern' doubt.

Next Steps

• Initiate a Phase 2a basket trial for VAR 200 in FSGS and Alport syndrome patients in Q2-2026.
• Advance IC 100 preclinical program toward a planned IND submission in Q4-2026.
• Initiate a Phase 1 trial for IC 100 in healthy overweight patients with a BMI between 27-30 at risk for cardiometabolic conditions following IND submission.
• Initiate IND-enabling preclinical studies for IC 100 in animal models of diet-induced obesity and an orphan renal disease in Q2-2026.
• Continue to identify and in-license additional drug candidates with significant clinical and commercial potential.
• Actively seek to obtain the broadest intellectual property protection possible for product candidates.
• Raise additional capital through public or private equity or debt financings or other sources.

Key Dates

Recommendation

The company's severe financial distress, evidenced by a substantial net loss, significant impairment charge, and a 'going concern' audit opinion, coupled with its delisting from Nasdaq to the less liquid OTCQB, presents an extremely high-risk investment profile. While the drug candidates show preclinical promise, the company's ability to fund their development to commercialization is highly uncertain. The current cash position is insufficient for long-term operations, necessitating further dilutive capital raises. Seasoned investors would likely view this as a strong sell due to the overwhelming financial challenges and existential risks.

Keywords

biopharmaceutical, clinical stage, renal disease, inflammatory disease, FSGS, Alport syndrome, diabetic kidney disease, cardiometabolic conditions, obesity, VAR 200, IC 100, Cholesterol Efflux Mediator, Inflammasome ASC Inhibitor, drug development, SEC filing, 10-K, going concern, Nasdaq delisting, OTCQB, impairment, biotech, pharmaceutical, drug discovery, clinical trials, preclinical development, intellectual property, regulatory approval, FDA, capital raise